-
Loading metrics
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
- Jane Harper,
- Katherine J. Adams,
- Giovanna Bossi,
- Debbie E. Wright,
- Andrea R. Stacey,
- Nicole Bedke,
- Ruth Martinez-Hague,
- Dan Blat,
- Laure Humbert,
- Hazel Buchanan,
- Gabrielle S. Le Provost,
- Zoe Donnellan,
- Ricardo J. Carreira,
- Samantha J. Paston,
- Luise U. Weigand,
- Martina Canestraro,
- Joseph P. Sanderson,
- Sophie Botta Gordon-Smith,
- Kate L. Lowe,
- Karolina A. Rygiel,
- Alex S. Powlesland,
- Annelise Vuidepot,
- Namir J. Hassan,
- Brian J. Cameron,
- Bent K. Jakobsen,
- [ ... ],
- Joseph Dukes
- [ view all ]
- [ view less ]
http://orcid.org/0000-0002-7705-1354
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
- Jane Harper,
- Katherine J. Adams,
- Giovanna Bossi,
- Debbie E. Wright,
- Andrea R. Stacey,
- Nicole Bedke,
- Ruth Martinez-Hague,
- Dan Blat,
- Laure Humbert,
- Hazel Buchanan
x
- Published: October 15, 2018
- https://doi.org/10.1371/journal.pone.0205491